Cargando…

p53 protects against formation of extrahepatic biliary precancerous lesions in the context of oncogenic Kras

KRAS and TP53 mutations are frequently observed in extrahepatic biliary cancer. Mutations of KRAS and TP53 are independent risk factors for poor prognosis in biliary cancer. However, the exact role of p53 in the development of extrahepatic biliary cancer remains elusive. In this study, we found that...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagao, Munemasa, Mizukoshi, Kenta, Nakayama, Shinnosuke, Namikawa, Mio, Hiramatsu, Yukiko, Maruno, Takahisa, Nakanishi, Yuki, Tsuruyama, Tatsuaki, Fukuda, Akihisa, Seno, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064879/
https://www.ncbi.nlm.nih.gov/pubmed/36999984
http://dx.doi.org/10.18632/oncotarget.28380
Descripción
Sumario:KRAS and TP53 mutations are frequently observed in extrahepatic biliary cancer. Mutations of KRAS and TP53 are independent risk factors for poor prognosis in biliary cancer. However, the exact role of p53 in the development of extrahepatic biliary cancer remains elusive. In this study, we found that simultaneous activation of Kras and inactivation of p53 induces biliary neoplasms that resemble human biliary intraepithelial neoplasia in the extrahepatic bile duct and intracholecystic papillary-tubular neoplasm in the gall bladder in mice. However, inactivation of p53 was not sufficient for the progression of biliary precancerous lesions into invasive cancer in the context of oncogenic Kras within the observation period. This was also the case in the context of additional activation of the Wnt signaling pathway. Thus, p53 protects against formation of extrahepatic biliary precancerous lesions in the context of oncogenic Kras.